Locust Walk

BioCapital LP Forum

Thursday, October 8, 2026

  • MassBioHub, 700 Technology Square 5th floor, Cambridge, MA
Apply to Attend
Add to Calendar +
AdobeStock_184492264

Overview

Why attend

Who should attend

On the agenda

Overview

A grounded case for biotech, in one room

The BioCapital LP Forum, co-hosted by Locust Walk and HSBC, is an invite-only, one-day gathering of family offices and institutional LPs in Boston on Thursday, October 8, 2026, bringing the senior decision-makers shaping biotech capital together for a grounded look at the opportunity, where it lives — funds, direct deals, and NewCo formation — and the relationships that make it investable. As capital crowds into technology and AI, many life-science companies trade at valuations that ignore the pace of the science, and the Forum makes the case for why now: biopharma M&A just hit a record ~$80B in a single quarter, even as dozens of biotechs still trade below cash. Strategic demand is real, and the entry point is attractive.

Why attend

What the Forum gives you

Conviction to act

A working command of biotech fundamentals and the structural forces positioning the sector for long-term value creation — in a year when biotech (the XBI) roughly tripled the broader market’s return.

A direct line to the market

Unfiltered insight from the investors, founders, and operators deploying capital in the sector today.

A clear path in

How to source deal flow and co-invest alongside experienced partners — with exit windows reopening on the strongest IPO quarter since 2021.

The right room

Decision-makers only, no gatekeepers, no junior staff.

WHO SHOULD ATTEND

The decision-makers shaping where capital goes next

The Forum is built for senior decision-makers who are already writing checks in biotech, or
currently evaluating commitments to the space:

ROLE

Partners and Managing Directors at family offices and institutional LPs

Wealth creators and owners – family principals in the true sense

EXPERIENCE

Investors already active in biotech, or sizing it up for the first time.

ACCESS

Invite-only and deliberately capped to keep the room senior — anyone may apply, and every applicant is vetted for credentials.

50

seats, by application only

APPLY TO ATTEND

On the agenda

A day built around education and access

A single day built around education, marquee voices, and high-quality networking: a market-setting keynote
followed by panels on direct vs. fund investing, NewCo formation, the AI-vs.-biotech debate, and how to 
begin investing in the space, closing with a networking reception.

8:30 – 9:00 AM

Registration

Registration & Breakfast

Arrivals, badges, and informal networking over breakfast.

9:00 – 9:30 AM

Opening

Welcome & Opening Remarks

Framing the day’s purpose, the state of biotech investing, the case for biotech as an asset class, and the U.S. private-venture market context.

Geoff Meyerson

Locust Walk & Banyan BioInnovations

9:30 – 10:30 AM

Panel 1

Direct Investing vs. Fund Investing

Trade-offs of going direct versus committing to funds; portfolio construction for LPs and family offices; reconciling fees against access and adverse selection.
Moderator

Alex Suriano

HSBC Private Bank

Ben Auspitz

Curie.Bio

10:30 – 11:00 AM

Break

Networking Break - Meet our Expert Speakers

Put your questions to the panelists directly, continue the on-stage discussion over coffee, and connect with fellow family offices and LPs in the room.

11:00 AM – 12:00 PM

Panel 2

Ground Floor: How NewCos Get Built and Financed

How new companies get built and financed, and where family offices and LPs can participate.

12:00 PM – 12:45 PM

Lunch

Lunch & Networking

Open networking over lunch.

12:45 – 1:30 PM

Keynote

Keynote: Andrew Lo of MIT Sloan School of Management

His TechTransferase model for financing and investing in biotech, and what it means for family offices and LPs.

Andrew Lo

MIT Sloan School of Management

1:30 – 2:30 PM

Panel 3

The AI-vs.-Biotech Debate

Where AI is genuinely reshaping drug development versus where hype outpaces reality; how investing in non-life-science AI competes with life-science investing; how investors best use AI to source, diligence, and decide.
Errik Anderson

Errik Anderson

Alloy Therapeutics & 82VS
Omar Khalil

Omar Khalil

Santé Ventures

2:30 – 2:50 PM

Break

Networking Break - Meet our Expert Speakers

Put your questions to the panelists directly, continue the on-stage discussion over coffee, and connect with fellow family offices and LPs in the room.

2:50 – 3:50 PM

Panel 4

The First Deal: A Playbook for Getting Started in Biopharma Investing

Practical tools and suggestions for LPs without in-house diligence capability to build it — for both funds and direct investments.
Barbara White

Barbara White

Banyan BioInnovations

3:50 – 4:00 PM

Closing

Closing Remarks

Synthesis of the day and next steps for the community.

4:30 – 5:30 PM

Reception

Networking Reception

Continuation of the day’s discussions over cocktails and curated introductions.

Hosts

Partners

Scroll to Top